Nick's public data
FILE UNDER EMBARGO
Understanding the contribution of operator measurement variability within flow cytometry data analysis for quality control of cell and gene therapy manufacturing
The management of risk and investment in cell therapy process development: a case study for neurodegenerative disease
Supplementary information files for article: 'Centralised versus decentralised manufacturing and the delivery of healthcare products: a United Kingdom exemplar'
Centralised versus decentralised manufacturing and the delivery of healthcare products: A United Kingdom exemplar
Richard P. Harrison
Decentralized manufacturing of cell and gene therapies: Overcoming challenges and identifying opportunities
Facilitating the operational readiness of the NHS for the in-house manufacture and delivery of autologous cell therapy 
Cryopreservation process development for clinical translation of a bioartificial liver support device [Abstract]
Manufacturability and ITS impact upon cell-based product process design [Abstract]
Pluripotent stem cell based medicinal products: A case study of process transfer related technical and manufacturing issues [Abstract]
Automating decentralized manufacturing of cell and gene therapy products.
Comparability: Manufacturing, characterization and controls, report of a UK Regenerative Medicine Platform Pluripotent Stem Cell Platform Workshop, Trinity Hall, Cambridge, 14-15 September 2015
Putting a price tag on novel autologous cellular therapies
Centralized or decentralized manufacturing? Key business model considerations for cell therapies
A 3D-bioprinting exemplar of the consequences of the regulatory requirements on customised processes
Overcoming the translational challenges of the effective administration and delivery of cells
Alexander M. Lyness
From production to patient: challenges and approaches for delivering cell therapies.